|Security||LJPC / La Jolla Pharmaceutical Co. (503459604)|
|President, CEO & Secretary||TIDMARSH GEORGE F|
|Form 4 Count||92|
|Form 8-K Count||79|
|Form SC 13G/A Count||34|
|Form 10-Q Count||18|
SEC Filings - 10K, 8K, Annual Reports
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to La Jolla Pharmaceutical Co.
Stop missing out on important events!
Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)
HEB / Hemispherx BioPharma, Inc.
AST / Asterias Biotherapeutics, Inc.
BIEI / Premier Biomedical Inc
CLDN / Celladon Corporation
Related News Stories
Today we will discuss Abeona Therapeutics (ABEO) after the company announced that it has nabbed a Rare Pediatric Disease designation from the FDA for ABO-202 for the treatment of CLN1 disease, which is a rare inherited disorder of the nervous system. (159-2)
For investors who have watched the staggering moves in bitcoin and somehow feel that they missed the bus, they were reminded last week when the cryptocurrency dropped back almost 35% just how insanely volatile the trade can be. While it may yet to prove to be the new standard for payment in the future, that sure won’t be the case anytime soon. (252-14)
How to find special situation and event-driven opportunities, merger arb and distressed investing are topics discussed and Value Detective shares a bullish thesis on PICO Holdings and Cision. (24-1)
The market potential for La Jolla's primary asset, a treatment for hypo-tension in Septic Shock patients, is severely overestimated in my opinion. (250-8)
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (418-2)